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BRCA1 haploinsufﬁciency for replication stress
suppression in primary cells
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BRCA1—a breast and ovarian cancer suppressor gene—promotes genome integrity. To study
the functionality of BRCA1 in the heterozygous state, we established a collection of primary
human BRCA1þ/þ and BRCA1mut/þ mammary epithelial cells and ﬁbroblasts. Here we report
that all BRCA1mut/þ cells exhibited multiple normal BRCA1 functions, including the support
of homologous recombination- type double-strand break repair (HR-DSBR), checkpoint
functions, centrosome number control, spindle pole formation, Slug expression and satellite
RNA suppression. In contrast, the same cells were defective in stalled replication fork repair
and/or suppression of fork collapse, that is, replication stress. These defects were rescued
by reconstituting BRCA1mut/þ cells with wt BRCA1. In addition, we observed ‘conditional’
haploinsufﬁciency for HR-DSBR in BRCA1mut/þ cells in the face of replication stress. Given
the importance of replication stress in epithelial cancer development and of an HR defect in
breast cancer pathogenesis, both defects are candidate contributors to tumorigenesis in
BRCA1-deﬁcient mammary tissue.
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erm line BRCA1 mutations increase greatly the risk of
breast and ovarian cancer1–3. While all cells of males and
females with germline BRCA1 mutations exhibit a
heterozygous BRCA1mut/þ genotype, cancer develops primarily
in females, often at young ages and almost exclusively affects the
breast and ovaries. Why BRCA1 is largely a breast and ovarian
cancer susceptibility gene, why males are largely protected from
BRCA1 cancer and how an ostensibly normal mammary epithelial
cell in a BRCA1 mutation carrier (BRCA1mut/þ) gives rise to
breast cancer cells are largely unknown.
In addition, there is insufﬁcient mechanistic insight into
BRCA1 breast tumorigenesis on which to base rational preventive
strategies. Their design will, in part, require a deeper appreciation
of the biological properties of a heterozygous but ostensibly
normal, mammary epithelium (BRCA1mut/þ).
The tumour-suppressing BRCA1 protein is an E3 ubiquitin
ligase and a multi-functional scaffold that binds numerous
partner proteins4,5. It plays a key role in genome integrity
maintenance, which appears to be an essential component of its
tumour-suppressing function2,5,6.
A BRCA1 loss of heterozygosity (LOH) event is a consistent
characteristic of fully developed BRCA1-linked tumour cells. Two
generic models describe the chain of events that precede it and
the concomitant emergence of mammary tumour cells (human
mammary epithelial cells (HMECs)). In one, HMECs, despite
being heterozygous, are histologically and biologically normal
before the emergence of LOH. They fail to exhibit a signiﬁcant
defect in BRCA1 function. Here key events that transform a cell
to malignancy follow the loss of all BRCA1 functions at the LOH
event and are often preceded by acquisition of a p53 mutation
that sustains cell viability in the face of emerging genome
disorder7.
In the other model, BRCA1mut/þ HMECs are haploinsufﬁcient
for the performance of one or more BRCA1 functions even
before any signs of a neoplastic cell phenotype emerge. This
model implies that, from the time that mammary epithelial
development is complete or at some relatively early
time thereafter, BRCA1mut/þ HMECs cannot perform all BRCA1
genome integrity maintenance functions at normal amplitude.
These abnormalities may increase the likelihood that steps in the
mammary tumorigenesis process begin long before they become
clinically apparent.
In this regard, there is growing evidence of a defect in normal
mammary epithelial progenitor differentiation in histologically
normal, BRCA1 heterozygous mammary tissue8–11, implying
that the second model is more likely valid than the ﬁrst.
Thus, determining whether BRCA1 heterozygosity confers
haploinsufﬁciency on HMECs for any of the multiple, known,
BRCA1 functions is a potentially valuable step in achieving
a better understanding of BRCA1 mutation-driven cancer
predisposition. In this regard, we have analysed a new
collection of primary mammary BRCA1mut/þ epithelial cells
and skin ﬁbroblasts obtained from BRCA1 mutation carriers for
such functions.
Results
Primary cell genotyping and lineage determination. Established
elements of BRCA1 function were analysed in freshly isolated,
morphologically non-neoplastic, primary HMECs and skin
ﬁbroblasts derived from multiple BRCA1þ/þ and BRCA1mut/þ
tumour-free women. Twenty-three primary BRCA1mut/þ ﬁbro-
blast cultures were derived from skin punch biopsies, and 15
primary BRCA1mut/þ HMEC cultures were generated from
individual prophylactic mastectomy samples (Table 1). HMECs
were cultured in serum-free medium.
The properties of BRCA1mut/þ HMECs were compared with
BRCA1þ/þ HMECs (N¼7), freshly derived from reduction
mammoplasty tissue, and those of BRCA1mut/þ skin ﬁbroblasts
with freshly isolated BRCA1þ/þ ﬁbroblasts (N¼11; Table 1).
Mutations in BRCA1 mutant ﬁbroblasts and HMECs were
conﬁrmed by homogenous Mass-Extend (hME) analysis12 and
by direct BRCA1 gene sequencing (Supplementary Fig. 1a–c).
Table 1 | Primary ﬁbroblast and HMEC strains (BRCA1þ/þ
and BRCA1mut/þ) used in this study.
Number Study ID Procedure Age Mutation
Fibroblasts
1 26 Skin Punch Biopsy 38 185delAG
2 32 Skin Punch Biopsy 55 185delAG
3 33 Skin Punch Biopsy 56 185delAG
4 34 Skin Punch Biopsy 29 Y1463X
5 39 Skin Punch Biopsy 50 S713X
6 45 Skin Punch Biopsy 49 5083del19
7 46 Skin Punch Biopsy 26 1137delG
8 47 Skin Punch Biopsy 48 185delAG
9 48 Skin Punch Biopsy 32 4184del4
10 53 Skin Punch Biopsy 52 185delAG
11 54 Skin Punch Biopsy 53 4154delA
12 57 Skin Punch Biopsy 27 185delAG
13 62 Skin Punch Biopsy 38 1294del40
14 65 Skin Punch Biopsy 36 3819del5
15 68 Skin Punch Biopsy 46 Q491X
16 69 Skin Punch Biopsy 30 5385insC
17 73 Skin Punch Biopsy 37 795delT
18 76 Skin Punch Biopsy 43 2530delAG
19 78 Skin Punch Biopsy 42 W1815X
20 80 Skin Punch Biopsy 49 185insA
21 82 Skin Punch Biopsy 62 185delAG
22 83 Skin Punch Biopsy 45 IVS19þ1G4A
23 1075 Skin Punch Biopsy 26 185delAG
1 WT Skin Punch Biopsy 56 N/A
2 1002 Skin Punch Biopsy 33 N/A
3 1004 Skin Punch Biopsy 58 N/A
4 1006 Skin Punch Biopsy 43 N/A
5 1007 Skin Punch Biopsy 50 N/A
6 1008 Skin Punch Biopsy 48 N/A
7 1009 Skin Punch Biopsy 69 N/A
8 1010 Skin Punch Biopsy 46 N/A
9 1011 Skin Punch Biopsy 58 N/A
10 AR8F Reduction Mammo 45 N/A
11 AR20L Reduction Mammo 31 N/A
Mammary Epithelial Cells
1 79 Proph. Mx 41 E143X
2 1046 Proph. Mx 28 3725C4T
3 1048 Proph. Mx 50 185delAG
4 CP10 Proph. Mx 43 1135insA
5 CP16 Proph. Mx 45 4065-4068del
6 CP17 Proph. Mx 28 2012insT
7 AR1 Proph. Mx 46 R1443X
8 AR9 Proph. Mx 34 1100delAT
9 AR10 Proph. Mx 28 1081G-4A
10 AR11 Proph. Mx 37 5385insC
11 AR12 Proph. Mx 48 R1203X
12 AR13 Proph. Mx 26 5385insC
13 AR14 Proph. Mx 38 5385insC
14 AR15 Proph. Mx 44 2530delAG
15 AR16 Proph. Mx 41 2983insT
1 CP14 Reduc. Mammo. 31 N/A
2 CP22 Reduc. Mammo. 49 N/A
3 CP29 Reduc. Mammo. 28 N/A
4 CP32 Reduc. Mammo. 38 N/A
5 AR4 Reduc. Mammo. 25 N/A
6 AR7 Reduc. Mammo. 33 N/A
7 N202 Reduc. Mammo. 27 N/A
N/A, not applicable.
Twenty-three primary ﬁbroblast strains were derived from skin punch biopsies and 15 primary,
mammary epithelial cell (HMECs) strains from prophylactic mastectomies (Proph. Mx) performed
on BRCA1 mutation carrying (BRCA1mut/þ) women. One primary ﬁbroblast strain (1075) was
derived from breast skin tissue obtained during prophylactic mastectomy. BRCA1þ/þ control
HMECs (n¼7) were derived from reduction mammoplasty tissue (Reduc. Mammo.), and control
ﬁbroblasts (n¼11) were derived from skin punch biopsies and reduction mammoplasties from
women lacking BRCA1 mutations.
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the entire BRCA1 genome (Fig. 1a).
To determine the lineage of cells that grew out of our primary
tissue samples under the culturing conditions used, we carried out
ﬂow cytometry (FACS)-based analysis of lineage markers (CD44,
CD49f, CD24 and EpCAM). In this study, our primary
BRCA1mut/þ and BRCA1þ/þ HMEC cultures were similarly
enriched in early basal (CD44high, CD24low, CD49fhigh
EpCAMlow) relative to luminal progenitor cells (CD44low,
CD49flow, CD24high, EpCAMhigh)9,13 (Supplementary Fig. 2a).
For this analysis, MCF7 was used as a luminal cell line control
and MCFDCIS.com as a basal cell line control.
Furthermore, western blot analysis of whole-cell (for HMECs)
and nuclear extracts (for ﬁbroblasts) revealed that full-length
BRCA1 expression in BRCA1mut/þ HMEC (Fig. 1b and
Supplementary Fig. 2c) and ﬁbroblast strains (Fig. 1c and
supplementary Fig. 2b) was lower than that detected in wt
BRCA1þ/þ lines. This was in keeping with the proven genetic
heterozygosity in these cells. As BRCA1 is much more abundant in
S and G2 than in G1, we only analysed wt and heterozygous
HMEC and ﬁbroblast cultures that exhibited similar cell cycle
proﬁles and BUdR uptake (see for example, Supplementary Fig. 2c).
Non-DNA repair-driven BRCA1 genome integrity functions.
BRCA1 exhibits two types of genome integrity maintenance
functions—those that are directed towards the repair of DNA
damage and checkpoint control, and others that sustain genome
integrity by contributing to homeostatic functions that are not
necessarily driven by DNA damage.
In this context, we asked whether the lower expression of
BRCA1 in BRCA1mut/þ cell cultures was associated with a
deﬁciency in the latter BRCA1 functions. BRCA1 is required for
the maintenance of centrosome number14, mitotic spindle pole
formation15–17, mammary development through the regulation of
master genes like Slug11 and heterochromatin-based satellite RNA
suppression18.
Each of these functions was compared in heterozygous
(BRCA1mut/þ) and control (BRCA1þ/þ) cells. Spindle forma-
tion was analysed by staining mitotic cells with a TPX2 antibody.
No abnormal spindle formation was detected in BRCA1mut/þ
cells (Fig. 2a and Table 1). The effects of robust BRCA1 depletion
on this function have been documented15.
Similarly, we found that none of the BRCA1mut/þ and
BRCA1þ/þ cells contained greater than 2 centrosomes, implying
that centrosome maintenance was normal in these different
BRCA1mut/þ strains (Fig. 2b and Supplementary Table 1).
Although we did not detect any evidence of centrosome
ampliﬁcation in multiple BRCA1 heterozygous cells, other work7
with BRCA1 heterozygous tissue has detected a small increase
of centrosome ampliﬁcation (B5%) in the epithelial cells of
heterozygous mammary tissue compared with 2.5% in wt tissue.
De-repression of satellite RNA transcription is also a feature of
BRCA1 mutant tumours18. Furthermore, Brca1 heterozygous
cells do not show evidence of satellite de-repression18. To test
whether this phenotype was present in heterozygous BRCA1
HMECs, two approaches were employed. Quantitative RT-PCR
(q-RT-PCR) was performed for alpha satellite variants (SATIII,
SATa and mcBox). Satellite RNA transcript levels were also
estimated by RNA FISH directed at another satellite RNA,
HSATII. Very low levels of satellite RNA were present in primary
HMECs, making it difﬁcult to detect any satellite RNA signal by
these methods (Supplementary Fig. 3a and b).
To address the effect of BRCA1 heterozygosity on Slug
expression11, we compared the Slug level in BRCA1þ/þ and
BRCA1mut/þ HMECs by western blot analysis. In these
experiments, MCF7 (a luminal breast cancer line) was used as a
negative control and MDA-MB-231 (a basal line) was used as a
positive control. No reproducible difference in Slug expression
was detected between the BRCA1þ/þ and BRCA1mut/þ strains
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Figure 1 | Distribution of BRCA1 mutations and BRCA1 protein in cells
derived from BRCA1 mutation carriers. (a) Cells were derived from skin
punch biopsies and prophylactic mastectomies performed on BRCA1
mutation carrying women. (b) Western blot analysis of total BRCA1 protein
levels in BRCA1mut/þ and BRCA1þ/þ HMEC lines. Equivalent amounts of
whole-cell lysate (prepared in NETN300) were electrophoresed, blotted
and the blots probed with an anti-BRCA1 monoclonal Ab (SD118). GAPDH
served as a loading control. (c) Western blot analysis of BRCA1 protein
levels in the nuclear fraction of BRCA1mut/þ and BRCA1þ/þ ﬁbroblast
strains. Cells were pre-lysed in pre-extraction buffer (PEB, details in
Materials and Methods), and the pellet was re-suspended in NETN400
buffer to prepare a nuclear extract. The intense BRCA1 band in 47
(185delAG, marked by an asterisk) is likely the previously discovered
truncated product of this mutant allele45. A non- speciﬁc band served as
the loading control.
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& 2014 Macmillan Publishers Limited. All rights reserved.that were tested (Supplementary Fig. 3c). Addition of serum11
had similar effect on Slug expression in BRCA1þ/þ and
BRCA1mut/þ strains.
DNA damage checkpoints. BRCA1 plays an important role in
regulating both the S phase and G2 checkpoints after DNA
damage19,20. The efﬁciency of post-damage checkpoint activation
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Figure 2 | Spindle pole formation, centrosome number, checkpoint activation and Rad51 recruitment to DSB. (a) Representative images of HMECs (left
panel) and skin ﬁbroblasts (right panel), from BRCA1mut/þ and BRCA1þ/þ were immunostained with an anti- TPX2 Ab to detect spindles; n¼50 spindles
were analysed for each strain. A summary of all strains that were tested in this assay is listed in supplementary Table 1. (b) Centrosome number was
determined by immunostaining HMECs (left panel) and ﬁbroblasts (right panel) with Ab to g-tubulin; n¼50 cells for each line were counted and cells with
centrosomes r2 were considered normal. A summary of the lines that were tested is presented in Supplementary Table 1. (c) S-phase checkpoint in
response to UV- and IR-induced DNA damage in control and BRCA1mut/þ strains. Three BRCA1þ/þ (AR7, CP22 and CP29) and three BRCA1mut/þ HMEC
strains (79, CP10 and CP16) were irradiated with increasing doses of UV (left panel). For IR-induced S-phase checkpoint analysis (right panel), cells were
exposed to IR (10Gy, red). Non-irradiated cells (0Gy, blue) served as controls. Error bars indicate the s.d. between the results of three, independent
experiments. (d) G2/M checkpoint activation in response to UV- and IR- induced DNA damage in BRCA1mut/þ and control cells. BRCA1þ/þ and
BRCA1mut/þ cells were irradiated with either UV (10Jm 2) or IR (10Gy), allowed to recover for 2h and then harvested for FACS analysis. The percentage
of cells in mitosis was determined by staining cells with propidium iodine (PI) and phosphorylated histone H3 (S28) antibody. Mock-irradiated (-Dam) cells
served as controls. (e) HMECs and (f) ﬁbroblasts were exposed to IR (10Gy) and allowed to recover for 4h. Cells were ﬁxed and co-immunostained with
Abs to g-H2AX and Rad51. Graphs depicting the fraction of cells with Rad51 foci that co-localized with g-H2AX foci for each line are plotted for both
HMECs and ﬁbroblasts (right panels in e and f). Mean and s.d. of at least three experiments for each strain are shown. wt BRCA1þ/þ (green) and
BRCA1mut/þ (red) lines.
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any signiﬁcant difference in the ability of BRCA1 þ/þ and mut/þ
lines to mount either an S phase (Fig. 2c, left and right panel) or a
G2 checkpoint response (Fig. 2d) following IR or UV-induced
DNA damage.
BRCA1 DNA repair functions double-strand break repair.
BRCA1 plays an essential role in homologous recombination-type
double-strand break repair (HR-DSBR)21,22. Defective HR-DSBR
is a well-known property of BRCA1 and related, inherited breast
cancers; molecular epidemiology results suggest that it is a risk
factor for these cancers23–25.
BRCA1 is attracted to discrete sites of DSB-containing damage,
where it directs a complex HR repair response5,26. Long-standing
results show that in BRCA1þ/  ES cells27, HR function is
normal until both copies of BRCA1 are inactivated (BRCA1 / ).
By contrast, others have reported that targeting one copy of
BRCA1 with a mutation (for example, 185delAG) in an
established, spontaneously immortal line of human HMECs
resulted in a subtle HR defect28. Thus, a detailed analysis of
multiple, primary human BRCA1mut/þ and BRCA1þ/þ HMECs
and ﬁbroblasts was undertaken to search for evidence of BRCA1
haploinsufﬁciency for HR-DSBR in this setting.
Two, well-validated assays were set up to measure HR-DSBR,
by testing the recruitment of Rad51 (an indicator of a key step
in HR)29 to sites of DSBs and by measuring the sensitivity to
PARP inhibitors (PI). The ﬁrst assay clearly showed that
BRCA1mut/þ cells were competent in recruiting Rad51 to sites
of DSBs (Figs 2e,f). Moreover, like HR-DSBR-competent cells,
they were also insensitive to olaparib (a PI). This assay, described
below, relies on the observation that sensitivity to a PI is
dependent on the existence of an HR defect30. Indeed, BRCA1
tumour lines (which lack functional BRCA1 and reveal a defect
in HR) are more sensitive to these agents than BRCA1þ/þ
cells31,32.
To study the effect of PARP inhibitors in our collection of
BRCA1mut/þ and BRCA1þ/þ cells, a FACS-based cell survival
assay of co-cultured cells was employed. Cells were ‘colour-coded’
and tested in pairs, where one cell strain emitted a ﬂuorescent
signal (for example, strain A, GFPþ) and the other (strain B) did
not. Strains A and B were mixed, co-plated and then exposed to a
DNA damaging agent of choice. After 7 days of recovery, they
were harvested and the relative abundance of each cell population
was analysed by FACS (Fig. 3a). The ratio of green/non-green or
non-green/green cells reﬂected the relative survival of the two
strains.
When BRCA1mut/þ and BRCA1þ/þ cells were compared for
their sensitivity to olaparib, BRCA1mut/þ cells were not found to
be demonstrably sensitive (Fig. 3b,c). As a positive control, U20S
cell line, made HR-DSBR incompetent by depleting BRCA1
(ShBRCA1 treated), was used along with control (ShLuc treated)
cells. Once BRCA1 depleted, these cells proved to be highly
sensitive to olaparib, while control cells were not (Fig. 3d).
In addition, BRCA1mut/þ HMEC viability was reduced by
olaparib, again only after BRCA1 depletion (siBRCA1, Fig. 3e).
Thus, despite the linkage of HR to BRCA1 breast cancer
suppression and in keeping with results obtained in mouse ES
cells27, these results, too, suggest that BRCA1mut/þ cells are not
defective for HR-dependent DSBR function.
Stalled replication fork repair. BRCA1 also protects the genome
from DNA damage resulting at stalled replication forks33–36.
It is rapidly attracted to these damage sites where it
joins other proteins that are required for stalled fork repair
(SFR). For example, BRCA1 is required for the generation of
phospho-RPA32-coated single-stranded DNA (ssDNA), a pre-
repair step needed for recruitment of ATRIP/ATR to activate the
intra-S and G2/M checkpoints that support SFR35,37–39.
In the absence of BRCA1, a stalled fork is more likely to be
bypassed by translesional synthesis35, or, it may collapse into
DSB, a hallmark of ‘replication stress’ and an established force in
support of epithelial cancer development40,41. In the mammary
epithelium, which undergoes normal periods of extreme
proliferation (for example, during pubertal development and/or
pregnancy), an accumulation of stalled forks, when not resolved,
is likely to result in signiﬁcant replication stress.
Thus, we asked whether BRCA1mut/þ cells are haploinsufﬁ-
cient in their ability to support SFR. Employing validated assays,
we found that, by comparison with control cells, BRCA1mut/þ
ﬁbroblasts and HMECs were defective in their SFR responses to
replication-stalling agents like hydroxyurea (HU) and UV-C
(ultraviolet radiation). We have shown previously that, in cells
that were heavily depleted of BRCA1, recruitment of phospho-
RPA32 (pRPA32) to chromatin was defective in response to
UV35. This defect was also evident after treatment with HU
(Supplementary Fig. 4a). When BRCA1mut/þ cells were tested for
their ability to recruit pRPA32 to chromatin after UV and/or HU
treatment, a defect was detected in BRCA1mut/þ cells (Fig. 4a–c,
and Supplementary Fig. 4a–d).
To test whether these abnormal RPA binding observations in
BRCA1mut/þ cells are speciﬁcally linked to BRCA1 haploinsufﬁ-
ciency, we asked whether ectopic wt BRCA1 expression in
BRCA1mut/þ cells corrects them. Infection by a lentiviral BRCA1
coding vector led to wt BRCA1 (HA-tagged) expression in
primary BRCA1mut/þ cells (Fig. 4f,g; Supplementary Fig. 5a).
This protein was recruited to DSBs and stalled forks in HMECs
and ﬁbroblasts like endogenous wt BRCA1 (Fig. 4f,g). Its
expression suppressed the apparent, post-UV haploinsufﬁcient
defect in pRPA32 chromatin recruitment (Fig. 4h,i, respectively).
Thus, this defect is a valid representation of BRCA1
haploinsufﬁciency.
To test the generality of SFR haploinsufﬁciency, we isolated
MECs from Brca1þ/  and Brca1þ/þ mice. These cells were
used to study the generation of phospho-RPA32-coated ssDNA
after UV- and HU-induced stalled fork formation. In keeping
with results obtained with BRCA1 heterozygous human cells,
we observed reduced phospho-RPA32 coating of ssDNA in
Brca1þ/  mouse cells compared with WT Brca1þ/þ cells
(Fig. 4d). This underscores the generality of the ﬁnding that cells
with one mutated allele for BRCA1 are haploinsufﬁcient for
pRPA32 loading on chromatin.
pRPA32 loading on chromatin is dependent on the generation
of ssDNA. Its generation after replication arrest is BRCA1-
dependent35. To detect the generation of ssDNA, a BrdU
immunoassay42 performed under non-denaturing conditions
(HCl) was used. Here, using the same assay, we found that
strain 39 (BRCA1mut/þ) generated less ssDNA (Supplementary
Fig. 4e,f) compared with strain 1002 (BRCA1þ/þ). This supports
the hypothesis that BRCA1mut/þ cells generate less ssDNA,
which in turn results in less pRPA32 chromatin loading.
Of note, 1075 (a human 185delAG/þ strain) failed to exhibit a
defect in ssDNA generation. This suggests that the post UV
generation of ssDNA was not affected in these cells and explains
why we did not observe a defect in pRPA32 loading in them.
Possibly, steps downstream of ssDNA generation and pRPA32
loading are defective in 185delAG strains (see for example,
below).
Finally, to test whether the inefﬁcient loading of RPA at stalled
forks in BRCA1mut/þ cells is a reﬂection of innately reduced RPA
activation after DNA damage, we assayed for RPA recruitment to
DNA in response to UV laser-induced DSBs. As shown in Fig. 4e,
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Figure 3 | FACS-based cell survival assay shows that HR-DSBR is not defective in BRCA1mut/þ cells. (a) FACS-based cell survival assay was used to
determine the sensitivity of cells to various DNA damage inducing agents. BRCA1mut/þ and BRCA1þ/þ ‘colour-coded’ cells were co-plated and exposed to
DNA damaging agents. Cell survival data are plotted as a ratio of GFP positive to GFP negative cells. Ratio between WT/WT(Green), Mutant/Mutant
(Blue) and Mutant/WT (Red) is plotted in the graphs below. (b) Combinations of BRCA1mut/þ and BRCA1þ/þ HMECs were exposed to different
concentrations of a PARP inhibitor, and the ratio of each of these combinations was plotted (left). The average ratio of WT/WT, Mut/Mut and Mut/WT
was also calculated and plotted (right). (c) (Left) Combinations of BRCA1mut/þ and BRCA1þ/þ ﬁbroblasts were exposed to different concentrations of a
PARP inhibitor, and the survival ratio of each of these combinations was plotted (left). An average ratio of WT/WT, Mut/Mut and Mut/WT was also
calculated and plotted (right). (d) U20S cells (containing or lacking a GFP reporter) were infected with ShLuc (control) or ShBRCA1 coding lentiviral
vectors. Green¼ratio of number of ShLuc-treated cells to ShLuc-treated cells, that is (ShLuc/ShLuc), Blue¼ratio of number of ShBRCA1-treated cells to
ShBRCA1 treated-cells, that is, ShBRCA1/ShBRCA1 and Red¼ratio of number of ShBRCA1-treated cells to ShLuc-treated cells, that is, ShBRCA1/ShLuc.
Averages of the results of individual experiments are plotted. (e) BRCA1mut/þ (CP10 and CP16) were transduced with shRNA directed at GAPDH
(siGAPDH) or BRCA1 (siBRCA1). Three days post transfection, combinations of siGAPDH or siBRCA1-transduced BRCA1mut/þ HMECs (CP10 and CP16)
were co-plated with AR7 (a BRCA1þ/þ HMEC) and exposed to various doses of a PARP inhibitor. Averages of the results generated by these combinations
were plotted. Error bars were calculated as the standard error propagation (SEP) in the ratios of each of the combinations in three independent
experiments.
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and þ/þ cells. This rules out the possibility of an innate defect
in RPA activation after DNA damage.
An inability to form pRPA32-coated ssDNA after DNA
damage may result in relevant checkpoint defects43. Although
we detected an incomplete reduction in pRPA32-coated
chromatin after UV-induced DNA damage in BRCA1mut/þ
HMECs, there was no obvious S or G2 checkpoint defect. Thus,
incomplete formation of pRPA32-coated ssDNA, in the
conditions tested, was, nonetheless, sufﬁcient to initiate a
proper checkpoint response.
Given that inefﬁcient loading of pRPA32 on ssDNA is
associated with an SFR defect, we asked whether BRCA1mut/þ
strains also experience an abnormally high frequency of collapsed
forks compared with their WT counterparts (BRCA1þ/þ). Fork
collapse can be captured by staining the cells with antibody to
53BP1 and/or g- H2AX, which is routinely recruited to these
damaged structures35,44.
BRCA1mut/þ cells, stained 18h post UV with p-S1778 53BP1
and g-H2AX Abs, revealed an increase in fork collapse by
comparison with wt controls (Fig. 5a,b). This again implies that
the efﬁciency of SFR is compromised in BRCA1mut/þ cells,
leading to higher fork collapse and incomplete resolution/repair
of these structures. Thus, BRCA1 is haploinsufﬁcient for the
suppression of replication stress in primary HMECs and
ﬁbroblasts.
Of note, 185delAG-bearing strains (that is, 26, 47, 53, 57,
AR19L) exhibited near normal loading of pRPA32 onto
chromatin (marked with asterisk in Fig. 4a and Supplementary
Fig. 4b), but more abundant 53BP1 foci by comparison with
control cells (Fig. 5b). Others have shown that the 185delAG allele
expresses a modestly truncated BRCA1 protein, translation of
which is initiated immediately downstream of the mutation near
the 50 end of the gene45. Thus, one might hypothesize that
185delAG is a hypomorph, capable of supporting some but not all
BRCA1 SFR support functions.
To better understand the fate of collapsed forks in
BRCA1mut/þ cells, we carried out DNA ﬁbre analysis. We
wished to assess two phenotypes: (1) the stability of nascent
replication tracts after fork stalling and (2) the efﬁciency of
replication restart. Cells were pulse labelled with IdU for 20min
followed by treatment with or without 5mM HU for 3h. After
washing off HU, cells were incubated in the presence of CldU for
30min (Fig. 5c). This protocol allows the analysis of the fate of
nascent replication tracts (synthesized before HU addition)
during replication stalling, as well as replication fork restart after
a replication block is eliminated (Fig. 5c).
DNA ﬁbre assays have been used previously with Brca1 / 
mouse ES cells to show that BRCA1 is required to suppress
degradation of nascent strands after replication stalling induced
by HU treatment36. In that study, replication restart was not
affected by the absence of BRCA1.
In keeping with these results, we ﬁnd that, in the presence
of HU, BRCA1mut/þ cells exhibited increased degradation
of the nascent strand (shorter green tracts) at stalled forks
compared with the BRCA1þ/þ cells (Fig. 5d,e; Supplementary
Fig. 5c). As shown in Fig. 5e, the distribution of nascent
DNA tract lengths (green tracts, Fig. 5d) for BRCA1þ/þ
MECs (CP32 and CP29) was not different between HU-treated
and -untreated samples (red and grey curves, respectively).
However, the red curves shifted towards shorter lengths
(increased degradation) after treatment with HU in
BRCA1mut/þ cells (CP10 and CP17). By contrast, no signiﬁcant
difference in the ability of BRCA1mut/þ cells to restart replication
was detected after replication stress had abated (Fig. 5c–e;
Supplementary Fig. 5c).
These results further support our conclusion that the stability
of stalled forks is compromised in BRCA1 heterozygous
(BRCA1mut/þ) cells.
To assess further the conclusion that inefﬁcient SFR
in BRCA1mut/þ cells results in increased DNA breaks, we
employed comet assays. In UV-treated cells there was a greater
increase in DNA breaks in BRCA1mut/þ when compared
with BRCA1þ/þ cells (Supplementary Fig. 5d,e). This result
reafﬁrms the ﬁnding that, faced with replication stalling, BRCA1
heterozygous primary cells exhibited signs of replication stress,
unlike BRCA1þ/þ cells.
Roles of BRCA1-associated proteins in SFR in BRCA1mut/þ
cells. A stalled fork serves as a scaffold to recruit and
concentrate proteins that play critical role/s in stabilizing, pro-
cessing, repairing and restarting a stalled fork. This is essential to
prevent the risk of its collapse into a DSB, a prime contributor to
genomic instability. We tested a subset of the proteins that
are known to be recruited to a stalled fork, with an eye towards
those that interact and/or function together with BRCA1 to carry
out SFR.
Speciﬁcally, we asked whether recruitment of Rad51, a BRCA1
partner in HR-based DSBR46,47 and a protein known to play an
HR-independent repair role at stalled forks48, is affected in
BRCA1mut/þ cells. We found that Rad51 recruitment to UV-
induced stalled forks was reduced in BRCA1mut/þ compared with
BRCA1þ/þ cells (Supplementary Fig. 6b). This was not
surprising, given that Rad51 is recruited to RPA-coated ssDNA,
the generation of which is compromised in BRCA1mut/þ cells.
We also found that the same BRCA1mut/þ strains that revealed
efﬁcient Rad51 recruitment to DSBs (Fig. 2e,f) were defective in
recruiting Rad51 to stalled forks. This implies that the role of
Rad51 at a stalled fork is different from that at a DSB and further
conﬁrms the observations made by other groups who found
that Rad51 helps restart stalled forks in an HR-independent
manner36,48,49. In addition, Scully et al.50 detected signiﬁcant
differences between the mechanism of repair at a non replication
fork-associated DSB and at a stalled fork-induced break.
We next assayed the efﬁciency of CtIP recruitment to UV-
induced stalled forks. CtIP is an established BRCA1 partner51 and
plays an important role in replication restart after stalled fork
formation52,53. We found previously that BRCA1 is required for
the recruitment of CtIP to UV-induced stalled forks35. In light of
this evidence, we asked whether CtIP recruitment is
compromised in BRCA1mut/þ cells. Just as for Rad51,
BRCA1mut/þ cells exhibited reduced CtIP recruitment to sites
of UV-induced fork stalling (Supplementary Fig. 6a). It is unclear
whether this defect in CtIP recruitment to stalled forks is a direct
result of a reduced BRCA1 protein level or reduced pRPA32-
coated ssDNA. Nonetheless, these data further conﬁrm that
BRCA1mut/þ cells are defective in SFR.
Finally, we addressed the fate of Mre11 at stalled forks in
BRCA1mut/þ and BRCA1þ/þ cells. Mre11 is a BRCA1-
associated nuclease that has been implicated in helping restart
collapsed and stalled replication forks via resection and initiation
of repair at these sites49,54,55. Given that BRCA1mut/þ cells
exhibit reduced ssDNA generation, defective pRPA32 loading
on chromatin and collapsed forks, we asked whether
Mre11 recruitment mirrors this phenotype. The data revealed
increased Mre11 recruitment to the sites of UV-induced stalled
forks in BRCA1mut/þ cells compared with BRCA1þ/þ cells
(Supplementary Fig. 6c). Given that Mre11 is a nuclease that is
recruited to DSBs, it seems reasonable to propose that increased
fork collapse in BRCA1mut/þ cells results in DSBs, that, in turn,
recruit Mre11. Thus, in lieu of possibilities discussed above,
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BRCA1mut/þ cells may be yet another indicator of the reduced
stability of stalled forks in BRCA1mut/þ cells.
Cell sensitivity to different DNA damage inducing agents.I n
an effort to validate the observation that primary BRCA1mut/þ
cells are defective for SFR and suppression of replication stress,
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agents, like UV and cisplatin56, was tested in differentially coloured,
co-cultured cells. In multiple comparisons of primary BRCA1mut/þ
and BRCA1þ/þ ﬁbroblasts and HMECs, the heterozygotes were
signiﬁcantly more sensitive than the wt cells to UV (Fig. 5e,f) and
cisplatin (Fig. 5g,h).
HR-DSBR in BRCA1mut/þ cells undergoing replication stress.
The discordance between multiple intact and one defective
BRCA1-associated functions in numerous, primary heterozygous
cell strains suggests that BRCA1mut/þ cells can preferentially
direct their limited stores of intact BRCA1 protein to checkpoint
activation, HR-DSBR, centrosome, SLUG control and spindle
pole function, and less effectively to SFR. Alternatively, less
BRCA1 protein is required for the former functions than the
latter one. In either case, we asked whether, when these cells
encounter sufﬁcient replication stress, BRCA1 becomes pre-
ferentially dedicated to SFR and, in doing so, the pool of BRCA1
available for otherwise intact functions is reduced. If it falls suf-
ﬁciently, do BRCA1mut/þ cells now become multiply hap-
loinsufﬁcient, that is, for other known BRCA1 functions that were
formerly intact in these cells.
To address this possibility, we pre-exposed cells to increasing
doses of UV and then assayed them for other BRCA1 functions
(other than SFR). To assay for HR, the UV-treated cells were
irradiated with IR and analysed for recruitment of Rad51 to DSBs
(Fig. 6a). To assay for spindle formation and centrosome
maintenance, we allowed the cells to recover for one and/or
two full cycles of cell division and then analysed the cells for
spindles as well as centrosomes.
As shown in Fig. 2e,f, multiple BRCA1mut/þ and BRCA1 þ/þ
cell strains recruited Rad51 to IR-induced DSBs with equal
efﬁciency in the absence of UV pre-treatment. However, the
ability of BRCA1mut/þ cells to recruit Rad51 to DSBs became
increasingly defective after exposure to increasing doses of UV
(Fig. 6a,b). No such effect was detected in BRCA1þ/þ cells. We
asked whether changes in BRCA1 protein levels in the UV pre-
treated heterozygotes could account for reduced Rad51 recruit-
ment, but no obvious alterations were observed (Supplementary
Fig. 4e). This result, along with the observation that Rad51
protein levels in BRCA1mut/þ and BRCA1þ/þ were also similar
(Fig. 6c), suggests that a defect in Rad51 recruitment to DSBs, in
UV- pretreated BRCA1mut/þ cells, is a result of a defect in the
ability of a limited pool of BRCA1 protein to respond to DSBs by
driving the HR-DSBR process.
To assess further the apparent emergence of ‘conditional
haploinsufﬁciency’ for HR-DSBR in the presence of replication
stress, we used the FACS-based assay described earlier to
determine the survival efﬁciency of BRCA1mut/þ cells in the
presence of olaparib. The question here was whether pre-
exposure of cells to stalled fork-inducing damage (for example,
UV) compromises the ability of these cells to carry out DSBR. If
so, the BRCA1mut/þ cells should become olaparib-sensitive.
Evidence presented in Fig. 6d showed this to be the case.
Exposure of BRCA1mut/þ cells to increasing doses of UV before
adding olaparib rendered them acutely sensitive to a relatively low
concentration of olaparib (Fig. 6d).
Centrosome number and spindle formation in the same cell
strains were not altered under these conditions (data not shown).
This implies that, at the very least, there is conditional
haploinsufﬁciency57 for HR-DSBR in BRCA1mut/þ cells facing
sufﬁcient replication stress.
Discussion
Multiple primary ﬁbroblast and HMECs derived from non-
tumour tissue of BRCA1 mutation carriers reveal, for the ﬁrst
time, the existence of BRCA1 haploinsufﬁciency for one of its
established, genome integrity maintenance functions, that is, its
ability to support SFR and to prevent replication stress. By
contrast, no such defect was detected among several other such
functions. Conceivably, haploinsufﬁciency for some of these
apparently unaffected BRCA1 functions occurs but takes
considerably longer to develop during the life of a BRCA1mut/þ
individual than did the defect in SFR. In addition, the quantity of
BRCA1 needed to sustain at least some of its other functions may
be signiﬁcantly less than that required for this activity.
Furthermore, in keeping with a model ﬁrst proposed by Bartek
et al.57, the data presented here also reveal a possible hierarchy of
DNA repair functions in BRCA1mut/þ cells, wherein a defect in
SFR, if not resolved, can trigger an otherwise undetectable defect
in HR-DSBR following enhanced replication stalling. In effect,
representative primary BRCA1mut/þ HMECs and ﬁbroblasts
exhibited a state of innate haploinsufﬁciency for SFR and
‘conditional’ haploinsufﬁciency for HR-DSBR.
Thus, in keeping with the model of Bartek et al.57,w e
hypothesize that, when the amplitude of replication stalling rises
above a threshold level in cells that are already deprived of a full
complement of intact BRCA1, the available BRCA1 pool is
dedicated ﬁrst to preventing and repairing collapsed forks. This
leaves even less BRCA1 available to form complexes that are
required for the execution of HR at DSB that are not associated
with fork collapse. The latter effect can be hypothesized to give
rise to the de novo development of an HR defect. This prediction
was borne out experimentally.
Figure 4 | BRCA1mut/þ cells derived from human and mouse tissue are defective in the generation of phospho-RPA32-coated ssDNA. (a) Phospho-
RPA32 (pRPA32) loading on chromatin is BRCA1 dependent. After UV-induced DNA damage, BRCA1mut/þ ﬁbroblasts exhibited reduced pRPA32 loading
on ssDNA, compared with BRCA1þ/þ lines. Cells were irradiated with 30Jm 2 of UVand harvested 3h post damage. Chromatin extracts were prepared,
and the relevant western blot was probed with an antibody to phosphorylated RPA32 (S4/S8). The replication status for each line was tested on the day of
the experiment by BrdU uptake measurement, and only those lines that exhibited similar replication proﬁles were analysed. A subset of lines tested is
shown here. Western blots for other WTand BRCA1 mutant lines are shown in Supplementary Fig. 4b. (b) BRCA1mut/þ ﬁbroblasts reveal reduced pRPA32
loading on ssDNA compared with BRCA1þ/þ lines, after HU exposure (10mM for 3h). An asterisk marks strains with the 185delAG mutation.
(c) BRCA1mut/þ HMECs reveal reduced pRPA32 loading on ssDNA, compared with BRCA1þ/þ HMECs after UV irradiation. (d) Mammary epithelial cells
derived from Brca1þ/  (L/10 and 3478/30) and/or Brca1þ/þ (V/1) mice were analysed for pRPA32 levels on chromatin after UV- and HU-induced
damage. (e) BRCA1mut/þ cells efﬁciently recruit RPA32 to DSBs. RPA32 loading at laser-induced DSBs was equivalently efﬁcient in BRCA1mut/þ and
BRCA1þ/þ lines. Cells were co-stained with anti- g-H2AX to reﬂect the existence of DSBs. (f) BRCA1mut/þ skin ﬁbroblasts (48) and (g) mammary
epithelial cells (CP17), each infected with a lentiviral vector expressing HA- tagged BRCA1, were either irradiated with 10Gy IR (upper panel) or 30Jm 2
of UV (lower panel). Cells were co-immunostained with Abs to BRCA1 and HA. (h,i) Phospho-RPA32 recruitment to ssDNA was analysed with a subset of
primary BRCA1mut/þ and BRCA1þ/þ ﬁbroblasts (h) and HMECs (i), infected with a lentiviral vector expressing either full-length WT BRCA1 (HA-tagged)
or eGFP (control). Western blots were immunostained with Ab to phospho-RPA32.
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integrity maintenance function, other than HR-DSBR, is
unknown. One possible explanation is that BRCA1 appears to
execute each of these unaffected functions as a member of a
large, multi-subunit complex(es)4,15,21,58,59. Conceivably, these
complexes are sufﬁciently stable, well-compartmentalized and
function efﬁciently enough before the onset of replication stalling
that they are not disadvantaged by such an event.
Given the strong contributory history of inadequate
SFR to epithelial cancer development and the fact that it is,
thus far, the only apparent haploinsufﬁcient BRCA1 DNA
repair abnormality, we speculate that SFR haploinsufﬁciency
serves as an early and persistent contributor to the long
process that gives rise to BRCA1 breast cancer (Fig. 6e). The
fact that, when exposed to sufﬁcient levels of replication
stress, conditional BRCA1 HR-DSBR haploinsufﬁciency
emerged in BRCA1 heterozygous cells suggests that this
defect might join SFR haploinsufﬁciency as a BRCA1 breast
cancer co-contributor in mammary epithelial progenitor cells
that are experiencing sufﬁcient ongoing replication stress. This
would beﬁt its widely accepted role as a major BRCA1 breast
cancer risk factor.
Assuming that other BRCA1 functions remain to be discov-
ered, it is conceivable that one or more of them, too, is
haploinsufﬁcient in the cells we have analysed. Thus, the current
picture, while new, may be incomplete.
BRCA1 haploinsufﬁciency for SFR was also apparent in
Brca1þ/  mouse MECs. Given that Brca1þ/  mice are not
tumour prone60, this suggests that haploinsufﬁciency for SFR in
mMECs is not sufﬁcient to drive tumorigenesis, especially given
the short life span of mice. Furthermore, despite the tissue
speciﬁcity (breast and ovary) of BRCA1 mutant cancer, a
haploinsufﬁcient phenotype was not limited to mammary
epithelial cells. Similar defects were also displayed by
BRCA1mut/þ ﬁbroblasts, thereby supporting the notion that
multiple factors combine to generate the tissue speciﬁcity of
BRCA1-mutant cancer.
Indeed, while drafting this manuscript, a new haploinsufﬁcient
role for BRCA1 was reported61. The authors showed that
transcription of the CYP1A gene, which encodes an estrogen-
metabolizing enzyme, is upregulated in BRCA1 heterozygous
cells61. In addition, Savage et al.61 showed that these oestrogen
metabolites result in increased DNA damage in BRCA1
heterozygous cells. In light of the existence of defective SFR in
BRCA1 heterozygous cells, it is reasonable to predict that such a
defect would be a key avenue through which haploinsufﬁciency
for oestrogen metabolite detoxiﬁcation could result in DNA
damage.
Even if SFR haploinsufﬁciency was not the only DNA repair
defect in BRCA1 heterozygous HMECs, the high potential for it to
give rise to chronic replication stress may well be clinically
signiﬁcant. This is because chronic replication stress is an
established and common force in human epithelial cancer
formation40,41,62,63.
Moreover, others have observed defects in differentiation in
populations of primary BRCA1mut/þ HMECs8–11. As yet
undeﬁned BRCA1 functional abnormalities underlie this set of
phenotypes and could, when deciphered, enlarge the results
described here. The extent to which SFR and, possibly,
conditional HR-DSBR haploinsufﬁciency contribute to them is
unknown but worthy of investigation. DNA damage is known to
perturb the differentiation of certain cell types64.
Recently, Winqvist et al.65 reported the existence of
haploinsufﬁciency for replication stress responsiveness in EBV-
immortalized B lymphocytes and primary T cells derived from
PALB2 heterozygotes. Their ability to perform HR was not
analysed. These data obtained from cells with a single PALB2
mutant genotype represent an example of haploinsufﬁciency for a
known BRCA1- and BRCA2- interacting protein that is also a
breast cancer suppressor. Thus, those results and evidence
reported here imply that haploinsufﬁciency in replication stress
suppression is a feature of ostensibly normal mammary epithelial
cells of two, different sets of mutation carriers.
In this regard, evidence of BRCA1 haploinsufﬁciency was
sought by Buchholz et al.66 in BRCA1 heterozygous ﬁbroblasts
and lymphocytes, and by Konishi et al.28 in a human HMEC line
where a BRCA1 mutation (185delAG) was introduced into one
allele by gene targeting. Buchholz et al.66 observed increased
sensitivity of BRCA1 heterozygous ﬁbroblasts to ionizing
radiation (IR) and increased chromatid breaks in lymphocytes
after IR. Given the pleiotropic effect of IR on DNA (for example,
strand breaks, fork stalling, base damage, DNA-adducts67–69),
one cannot rule out that the sensitivity to IR is a result of
contribution of multiple forms of DNA damage and not just a
response to DSB formation.
Similarly, in Konishi et al.28 it was suggested that the targeted
heterozygous clones were defective in HR-DSBR. Although
increased sensitivity of these clones to IR and a reduced HR-
DSBR signal in HR reporter-containing cells were detected, they,
like we, failed to observe any sensitivity of their BRCA1mut/þ
cells to PARP inhibition, raising a question regarding the
existence of an HR defect. Given that the test cells were
reported to be slow to proliferate, this could have contributed
towards apparent HR deﬁciency.
The possibility that persistent replication stress is a tumour-
promoting force in BRCA1mut/þ mammary epithelial cells offers,
Figure 5 | The stalled fork repair pathway is defective in BRCA1mut/þ cells. Heterozygous BRCA1mut/þ cells reveal increased DNA break formation, after
stalled fork-inducing DNA damage, show reduced replication fork stability, and are more sensitive than WT BRCA1þ/þ cells to stalled fork-inducing agents.
After exposure to a stalled fork-inducing agent (UVand/or HU), BRCA1mut/þ cells were prone to increased fork collapse compared with BRCA1þ/þ cells.
(a) Skin ﬁbroblasts, and (b) HMECs derived from BRCA1 mutation carriers (BRCA1mut/þ) and wild type BRCA1 counterparts (BRCA1þ/þ), were
irradiated with low dose UV (5Jm 2) and allowed to recover for 18h. Cells were immunostained with Ab to 53BP1 and g- H2AX (a marker for collapsed
replication forks). The right (R) panel depicts the percentage of cells with Z10 53BP1 foci per cell in HMECs and ﬁbroblasts. Mean and s.d. of at least
three experiments for each strain are shown (green: wt BRCA1þ/þ;r e d :BRCA1mut/þ). (c) Schematic representation of DNA ﬁbre experiment.
(d) Representative tracts from DNA ﬁbre experiments with HMECs (BRCA1þ/þ , CP29; BRCA1mut/þ, CP10) treated with 5mM HU for 3h. Green and red
tracts correspond to IdU and CldU incorporation, respectively. Red scale bar represents 10mm length. (e) Distribution curves of IdU tract lengths
in the presence and absence of HU (5mM for 3h) for both BRCA1þ/þ (ﬁrst two plots, CP32 and CP29) and BRCA1mut/þ (last two plots, CP10 and CP17)
cells. Red and Grey curves represent the presence and absence of HU in the culture medium, respectively. At least 200 tracts were scored for each
distribution curve. (f,g) (Left panels) Combinations of BRCA1mut/þ and BRCA1þ/þ HMECs (f) and ﬁbroblasts (g) were irradiated with different doses
of UV. (Right) Average of data plotted on left. (h) Combinations of BRCA1mut/þ and BRCA1þ/þ HMECs and (i) ﬁbroblasts were incubated with
increasing concentrations of cisplatin for 15h. Cells were allowed to recover for 6 days and then harvested for FACS analysis. Panels on the right show the
averages of data plotted on the left.
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prevention. If speciﬁc subsets of BRCA1mut/þ HMECs normally
advance beyond the manifestation of an SFR defect to develop
additional BRCA1 functional deﬁciencies accompanied by a much
higher risk of tumorigenicity, their selective elimination might
suppress subsequent BRCA1 breast cancer development.
Rad51 γ-H2AX Merge
B
R
C
A
1
+
/
+
 
(
C
P
2
9
)
B
R
C
A
1
m
u
t
/
+
 
(
C
P
1
6
)
WT_CP29/WT_CP29 WT_CP32/WT_CP32 Mut_CP16/Mut_CP16 Mut_079R/Mut_079R Mut_CP16/WT_CP32 Mut_79R/WT_CP32 Mut_CP16/WT_CP32
0
J
 
+
 
1
0
G
y
80
0 J m–2
5 J m–2
10 J m–2
15 J m–2
70
60
50
40
30
20
10
0
AR7
CP22
CP29
CP17
AR7
CP29
CP10
CP16
79
CP29
39
28
28
28
51
39
39
39
Rad51
GAPDH
BRCA1+/+ BRCA1mut/+
CP22 CP32
Patient ID
(BRCA1+/+)
(BRCA1mut/+)
(BRCA1+/+)
(BRCA1mut/+)
79 CP10 CP16 CP17
1
5
J
 
+
 
1
0
G
y
0
J
 
+
 
1
0
G
y
1
5
J
 
+
 
1
0
G
y
1.40
1.20
1.00
0.80
0.60
0.40
s
u
r
v
i
v
a
l
 
r
a
i
o
0.20
0.00
UV
BRCA1
+/– Defective
stalled fork repair
and ? MEC differentiation
p53 mut
Replication stress
genomic instability
BRCA1 LoH
Breast cancer
p53 +/+
SFR haplo
HR cond_haplo
Others + or ?
Ostensibly normal
UV UV
Patient sample ID and experimental set up
UV+PI
(0.2 μM)
UV+PI
(0.2 μM))
UV+PI
(0.2 μM)
UV UV+PI
(0.2 μM)
UV UV+PI
(0.2 μM)
UV
*
**
*
* *
* *
* *
*
*
UV+PI
(0.2 μM)
UV UV+PI
(0.2 μM)
BRCA1+/+/BRCA1+/+ BRCA1mut/+/BRCA1mut/+ BRCA1mut/+/BRCA1+/+
0 J m –2
3 J m –2
6 J m –2
9 J m –2
%
 
C
e
l
l
s
 
w
i
t
h
 
R
a
d
5
1
 
f
o
c
i
 
c
o
l
o
c
a
l
i
z
e
d
w
i
t
h
 
γ
-
H
2
A
X
 
f
o
c
i
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6496
12 NATURE COMMUNICATIONS|5:5496|DOI: 10.1038/ncomms6496|www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.Methods
Isolation and culture of human MECs and ﬁbroblasts from tissue biopsies.
Tissue samples were brieﬂy washed in PBS and then minced and digested overnight at
37C in medium containing 1mgml 1 of collagenase type III (Roche). For digestion,
MEGM medium (Lonza) was used for breast tissue, and Dulbecco’s modiﬁed Eagle’s
Medium (DMEM) with 5% fetal bovine serum (FBS) for skin tissue. The digested
tissue was pelleted and ﬁbroblasts were cultured in DMEM supplemented with 15%
FBS (Gibco), 1% Pen/Strep (Gibco) and 1% Glutamine (Gibco), and HMECs were
grown in MEGM medium supplemented with 1% Pen/Strep.
Isolation and culture of mouse MECs from mouse mammary tissue. Primary
mouse MEC cultures were generated from the 4th and 5th pairs of mammary fat pads
using a sterile technique. The tissue was digested overnight at 37C in serum-free
Leibovitz-15 medium containing 3mgml 1 of collagenase A (Sigma). Digestion was
stopped by adding 1  volume of 10% serum containing DMEM. The pelleted cells
and organoids were plated and cultivated in DMEM/F12 50:50 medium supple-
mented with 10% FCS, 50unitsml 1 penicillin, 50mgml 1 streptomycin (Life
Technologies), 5mgml 1 recombinant human insulin (Sigma), 5ngml 1 recombi-
nant human EGF (Sigma) and 5ngml 1 cholera toxin (Calbiochem).
Mouse model and genotyping. The mouse Brca1 null allele used in this study was
generated by crossing mice harbouring the BRCA1F5-13 conditional allele (kindly
provided by Dr Jos Jonker’s group)60 with Meox2-Cre deleter mice purchased from
Jackson Labs (Bar Harbor, ME—Stock #003755). Mouse genotyping was performed
on genomic DNA extracted from mouse-tail snips using standard procedures60.
Genotyping for Cre-generated Brca1 null allele was carried out with primers
GenoB1-A (50-AGGTACCAGTTATGAGTTAGTCGTGTGCCTGAGTCA-30) and
GenoB1-D (50-GGCTACCTATAACTACTCTCTAACAACGAAGTGCAA-30),
which yielded a 654-bp fragment. The wt brca1 allele was genotyped using primers
GenoB1-A and GenoB1-B (50-GCTGAGATTAAAGTGCAGGCCACCACACTCA
GTGAT-30), which yielded a PCR product of 495bp for the wt allele and 624bp for
the ﬂoxed allele. PCR ampliﬁcation conditions used were as described previously60.
Primers Meox2Cre1 (50-CCTGAAAGCAGTTCTCTGGGACCACCTTCTTTTGG
CTTC-30) and Meox2Cre2 (50-CTTCTTCTTGGGTCCTCCCAGATCCTCCTCAG
AAATCAGC-30) were used to verify the presence of Meox2 Cre allele. Ampliﬁed
fragment was 423bp.
Transfection, infection and selection. For siRNA experiments, cells were grown
in six-well plates and transfected with 100pmoles of siRNA with RNAiMAX
(Invitrogen) according to the manufacturer’s protocol. Where relevant, experi-
ments were initiated 48h after transfection. All siRNA oligonucleotides were
purchased from Thermo Scientiﬁc. siRNA oligonucleotides used were siBRCA1
(On Target Plus BRCA1, catalog number CTM-41735) and siGAPDH (On Target
Plus GAPDH, catalog number D-001830-01-20). For shRNA experiments, shRNA
encoding lentiviruses were generated using 293FT-packaging cells in the presence
of lipofectamine (Invitrogen). Cells infected with puroR-encoding lentiviruses were
selected transiently using 2.5mgml 1 puromycin (Santa Cruz). ShBRCA1 and
shLuc were acquired from The RNAi Consortium (TRC). The target sequence for
shBRCA1 was 50-AGAATCCTAGAGATACTGAA-30. For BRCA1 reconstitution
experiments, lentiviral packaging plasmids, VSVG and PSPAX, were used to
package BRCA1 and/or eGFP plasmids in 293FT cells using lipofectamine (Invi-
trogen). Cells were infected with the lentivirus and selected using 6mgml 1 of
Blasticidin (Invitrogen). For colour-coding experiments, hTERT and GFPhTERT
containing retroviruses were prepared by packaging the plasmids pMIG-hTERT
and pBABE-hygro-hTERT with the retrovirus packaging plasmids, pMD-MLV and
pMD-G, in 293FT cells. hTERT-infected cells were selected with hygromycin B
(Roche) (50mgml 1).
Immnoblotting and antibodies. Whole-cell extracts were prepared by lysing cells
in NETN300 lysis buffer (300mM NaCl, 20mM Tris–HCl buffer pH7.8, 0.5% NP-
40, 1mM EDTA) for 1h at 4C. Nuclear extracts were prepared by pre-extracting
the cytoplasmic protein fraction by incubating the cells in pre-extraction buffer,
that is, PEB (0.5% Triton -X-100, 20mM HEPES pH 7.0, 100mM NaCl, 3mM
MgCl2 and 300mM Sucrose). Incubation was carried out at 4C for 20min. Cells
were pelleted, washed once in PEB, and lysed in NETN 400 lysis buffer
(400mM NaCl, 20mM Tris-HCl buffer pH7.8, 0.5% NP-40, 1mM EDTA) for
45min at 4C. All lysis buffers were supplemented with 1  protease inhibitor
(Roche) and Halt Phosphatase inhibitor (Thermo Scientiﬁc). Chromatin extracts
were prepared as described previously43. Immunoprecipitation for HA- tagged
BRCA1 was carried out by incubating whole-cell extracts with an HA antibody
(Covance) for 2h, followed by 1h incubation with Protein A beads (GE healthcare)
at 4C. The beads were washed in NETN 150 buffer (150mM NaCl, 20mM
Tris–HCl buffer pH7.8, 0.5% NP-40, 1mM EDTA). Antibodies used for
western blotting were phospho-RPA32 (Bethyl Labs, A300-245A; 1:2,000), BRCA1
(SD118; 1:1,000), GAPDH (Santa Cruz, SC-25778; 1:4,000), pS53BP1-S25 (Novus
Biologicals, NB100-1803; 1:5,000), Rad51 (Santa Cruz, SC-8349; 1:600), Slug
(Cell Signaling, C19G7; 1:3,000), Vinculin (Santa Cruz, SC-55465; 1:1,000),
BRCA1 (MS110; 1:1,000) and HA (Covance, MMS-101P; 1:4,000). Uncropped
western blots for Figs 1,4,6, and Supplementary Figs 2–5 are shown in
Supplementary Fig. 7.
Immunoﬂuorescence and antibodies. Cells on coverslips were ﬁxed with 4%
paraformaldehyde/2% Sucrose for 15min, and triton extracted (0.5% Triton X-100
in PBS) for 4min. Cells were blocked with 5%BSA/PBST and then incubated with
respective antibodies for 30min at 37C followed by incubation with secondary
antibodies (FITC or Rhodamine) for 30min at 37C. Primary antibodies used
in immunoﬂuorescence studies were BRCA1 (Upstate; 1:500), phospho-
53BP1(S1778) (Cell Signaling, 2675S; 1:200), RPA (Cal Biochem, NA13; 1:100),
53BP1 (Bethyl Labs, A300-272A; 1:2,000), Rad51(Santa Cruz, SC-8349; 1:150),
Mre11 (Genetex, GTX70212 1:200), CtIP (generous gift from Dr. Richard Baer),
HA (Covance, MMS-101P; 1:500) and g-H2AX (Millipore, 05-636; 1:5,000).
For TPX2 (Bethyl Labs, A300-429A; 1:400) and g-tubulin (Sigma- Aldrich,
T6557; 1:1,000) staining, the cells were pre-ﬁxed with acetone:methanol (3:7) at
 20C for 10min, followed by triton extraction (0.2% triton-X-100 in
20mM HEPES, pH 7.4, 50mM NaCl, 3mM MgCl2, 300mM Sucrose) at
room temperature. Primary and secondary antibody staining was carried out
as described above.
Cell treatments. For analysis of phospho-RPA32 loading on chromatin, cells were
treated with stalled fork inducing agents like HU (Sigma) and/or UV. Cells were
incubated in HU (10mM)-containing medium for 4h before harvesting for further
analysis. For UV treatment, cells were irradiated with 30Jm 2 UV with a 254nm
UV-C lamp (UVP Inc., Upland, CA) and harvested 4h post UV. UV-irradiation
through a micropore membrane was performed as described previously43. For
colour- coded FACS-based cell survival assays, the Parp inhibitor, olaparib
(Selleck), was added at ﬁnal concentrations of 0.2, 0.4 and 0.6mM for 6 days.
cisplatin (Novaplus) was added at ﬁnal concentrations of 0.5, 1.0 and 1.5mM for
24h. Medium was replaced, and the cells were allowed to grow for ﬁve more days.
The doses of UV used were 5, 10 and 15Jm 2, and cells were allowed to recover
for 6 days before they were harvested for FACS analysis. Laser-induced DNA
breaks were generated as described in Greenberg et al.4
DNA ﬁbre assay. DNA ﬁbres were prepared and analysed as described pre-
viously48,49 with a few modiﬁcations. In brief, cells were labelled with 25mMI d U
for 20min, washed two times and incubated in presence of 5mM HU for 3h. This
Figure 6 | Evidence of conditional haploinsufﬁciency for DSBR in BRCA1mut/þ HMECs after pre-exposure to a stalled fork- inducing agent.
(a) Recruitment of Rad51 to IR-induced DSBs is reduced in heterozygous BRCA1mut/þ, and not in WT BRCA1þ/þ HMECs, when pre-exposed to stalled
fork-inducing damage. HMECs derived from a BRCA1 mutation carrier (CP16, BRCA1mut/þ) and a wt counterpart (CP29, BRCA1þ/þ) were irradiated
with different doses of UV (5, 10 or 15Jm 2) and allowed to recover for 1h. Cells were then irradiated with IR (10Gy) and ﬁxed 4h post IR. Fixed cells were
coimmunostained with Abs to g-H2AX and Rad51. Additional wt and heterozygous strains were also assayed (in panel b). (b) Additional BRCA1þ/þ
and BRCA1mut/þ strains were analysed as described in (a). A graph depicting the fraction of cells in each additional HMEC strain that contains Rad51 foci
after exposure to increasing doses of UV followed by 10Gy dose of IR was plotted. The mean results and s.d. of data from at least three experiments
are shown for each line. (c) Rad51 expression in BRCA1mut/þ and BRCA1þ/þ HMEC lines. Whole-cell extracts from various BRCA1mut/þ and BRCA1þ/þ
strains were analysed by western blot. GAPDH was used as a loading control in these blots. (d) Combinations of BRCA1mut/þ and BRCA1þ/þ HMECs
(green: BRCA1þ/þ/BRCA1þ/þ, blue: BRCA1mut/þ/ BRCA1mut/þ and red: BRCA1mut/þ/BRCA1þ/þ) were irradiated with different doses of UV
(0, 3, 6 and 9Jm 2), allowed to recover for 1h, and then treated with either 0.2mM PARP inhibitor (PI¼olaparib; UVþPI) or DMSO as control (UV).
Cells were grown for ﬁve more days before harvesting for FACS analysis. Data are plotted for the three, different cell combinations, and the error bars were
calculated as the standard error propagation (SEP) in the ratios of each of the combinations in three, independent experiments. Data marked with an
asterisk (*) reveal statistically signiﬁcant differences (P-value o0.05) between UV and UVþPI sets. (e) One Possible Model of BRCA1 mutation- driven
tumorigenesis. This model speculates that certain abnormal developments might occur during the extended period between full mammary development
and the appearance of a BRCA1 breast cancer.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6496 ARTICLE
NATURE COMMUNICATIONS|5:5496|DOI: 10.1038/ncomms6496|www.nature.com/naturecommunications 13
& 2014 Macmillan Publishers Limited. All rights reserved.was followed by incubation with 250mM CldU for 30min. Labelled cells were
harvested, mixed 1:5 with unlabelled cells, lysed and spread on slides to
obtain single-DNA tracts. After ﬁxation, denaturation and blocking, the DNA
tracts were stained with rat anti-CldU (Abcam, ab6326), followed by staining with
a secondary antibody Alexa ﬂuor 555 goat anti-rat overnight at 4C. DNA
tracts were then stained with mouse anti- IdU (BD Biosciences, 555627) followed
by a secondary antibody Alexa- 488 goat anti mouse. ImageJ software was
used for determining the tract lengths based on scale bar generated during
microscopy.
Detection of ssDNA (BrdU ssDNA Assay). BrdU ssDNA assay was performed
as described previously42. In brief, cells on coverslips were cultured with 30mM
BrdU for 20h, and then released in BrdU-free medium for 16h. Cells were stained
as described previously42.
Sequencing and hME. Cells lines were sequenced to conﬁrm their mutations via
direct sequencing or by the hME sequencing method. Genomic DNA was prepared
from Blood and a DNeasy kit (Qiagen), and a mutation locus-speciﬁc PCR reaction
was carried out to amplify the region of interest. For direct sequencing, the
ampliﬁed PCR products were puriﬁed using a Qiagen PCR puriﬁcation kit and
were sent for sequencing. For hME analysis, a locus-speciﬁc primer extension
reaction of the PCR ampliﬁed region was carried out in the presence of a mixture of
di-deoxy and deoxy NTPs. Allele-speciﬁc extension products were analysed by
mass spectrometry to determine the speciﬁc sequence. More details of the protocol
are available at the following link: http://cancer-seqbase.uchicago.edu/documents/
AssayDesign3.1Guide.pdf
Comet assay and analysis. For detection of DNA breaks, alkaline comet assays
were performed using the Single-Cell Gel Electrophoresis Assay kit (Trevigen)
according to the manufacturer’s instructions. The quantiﬁcation of tail DNA was
carried out using CellProﬁler software.
Flow cytometry, checkpoints and colour-coding-based cell survival FACS
assay. For cell cycle analysis, cells were pulse-labelled with 10mM BrdU for 30min
(for HMECs) and 1.5h (for ﬁbroblasts) in respective culture media. Single-cell
suspensions were ﬁxed in 70% ice-cold ethanol. Cells were incubated with an anti-
BrdU FITC conjugate antibody (Becton Dickinson, 1:10 dilution made in Blocking
solution from Thermo Scientiﬁc) at room temperature in the dark for 45min.
Finally, the cells were resuspended in propidium iodide and RNAse staining buffer
(Becton and Dickinson) and analysed using a Becton Dickinson FACS (Mountain
View, CA).
For checkpoint assays, cells were irradiated with UV and/or IR and allowed to
recover for 2h. For S-phase checkpoint analysis, cells were incubated with BrdU, as
described above, before harvesting and ﬁxing for FACS analysis. For G2
checkpoint, ﬁxed cells were incubated with an Alexa Fluor anti-phospho-histone
H3 (Ser10) antibody diluted in 2% BSA/PBS at room temperature in the dark for
2h. Cells were washed and resuspended in propidium iodide and RNAse-
containing staining buffer.
For colour-coded FACS-based assays, GFP-positive and -negative cells were
mixed in equal numbers (8,000 cells per strain) and plated in 6cm2 plates. After
drug and/or UV treatment, cells were allowed to recover for 6 days before being
harvested for FACS analysis.
Satellite RNA q-RT-PCR. Cells grown in 6cm2 plates were collected, RNA was
prepared using an RNeasy Plus Mini Kit (Qiagen), followed by cDNA preparation.
q-RT-PCR was carried out with primers for SatA, SatIII, mcbox and b-Actin. More
details and primer sequences are described in Zhu et al.18
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